Premium
Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis
Author(s) -
Wiegand J.,
Maasoumy B.,
Buggisch P.,
Buslau A.,
Schiefke I.,
Berg T.,
Wedemeyer H.,
Sarrazin C.,
Hinrichsen H.
Publication year - 2014
Publication title -
alimentary pharmacology and therapeutics
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.12748
Subject(s) - medicine , telaprevir , gastroenterology , ribavirin , tolerability , population , hepatitis c , hepatitis c virus , surgery , adverse effect , immunology , virus , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom